NASDAQ
TLSI
Last Price
US $4.69
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
TriSalus Life Sciences, Inc. cash flow to debt ratio of -52.30% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial stability - Healthy cash flow growth.
TriSalus Life Sciences, Inc.'s free cash flow has increased -54.04% from $-41.19M last year to $-18.93M, signaling increasing performance
Financial risk - Healthy debt to equity ratio.
TriSalus Life Sciences, Inc.'s debt to equity ratio is 2.69, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy
Financial risk - Healthy debt to equity ratio development.
TriSalus Life Sciences, Inc.'s debt has increased relative to shareholder equity from -0.91 last year to 2.69 today, signaling weakened financials
Financial risk - Net debt/EBITDA.
TriSalus Life Sciences, Inc. has negative EBITDA, making leverage ratio unreliable
Financial risk - ICR.
TriSalus Life Sciences, Inc.'s interest coverage ratio is -4.86, which means that the company struggles to meet interest obligations, signaling financial risk.
Financial stability - Profit margin growth.
TriSalus Life Sciences, Inc.'s profit margin has increased (-46.11%) in the last year from -112.92% to -60.85%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
TriSalus Life Sciences, Inc.'s short-term assets of $32.24M exceed its short-term liabilities of $11.50M
Decreasing performance - ROA.
TriSalus Life Sciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Increasing performance - Absolute return on equity.
TriSalus Life Sciences, Inc.'s return on equity of 162.57%, is higher than 15.00%, indicating good performance
Decreasing performance - Earnings quality.
TriSalus Life Sciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
TriSalus Life Sciences, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
TriSalus Life Sciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
TriSalus Life Sciences, Inc. has negative free cash flow, indicating cash burn
Decreasing performance - Healthy earnings growth.
TriSalus Life Sciences, Inc.'s yearly earnings has decreased 18.04% since last year from $-33.23M to $-39.23M, signaling decreasing performance
Increasing performance - Healthy revenue growth.
TriSalus Life Sciences, Inc.'s yearly revenue has increased 53.41% since last year from $29.43M to $45.15M, signaling increasing performance
Decreasing performance - ROIC.
ROIC -47.18% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Increasing performance - 3-year revenue CAGR.
TriSalus Life Sciences, Inc.'s 3-year revenue CAGR of 53.85% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
TriSalus Life Sciences, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
TriSalus Life Sciences, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
TriSalus Life Sciences, Inc. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
TriSalus Life Sciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
TriSalus Life Sciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
TriSalus Life Sciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
TriSalus Life Sciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - P/B ratio.
TriSalus Life Sciences, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails
Undervalued - P/S ratio.
TriSalus Life Sciences, Inc. has a price-to-sales ratio of 4.00x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
162.57%
Return on equity
ROIC: -47.18%
Valuation History
-3.4X
Price to Earnings
EV/EBITDA: -7.5X
Cash flow
Profit margin
-53.59%
(FY vs FY)
Cash flow Y/Y
-48.62%
(FY vs FY)
Fair Value
Market $4.69
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.